Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370704 · ClinicalTrials.gov registry record · Phase 1
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
A Phase 1 study of Melanoma, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 17
- Study locations
NCT04370704: Completed Phase 1 study of Melanoma, sponsored by Incyte Corporation.
NCT04370704 is a Phase 1 study of Melanoma that has completed, run by Incyte Corporation. The registered enrollment target is 61 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04370704, a Phase 1 study of Melanoma, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 17
- Study locations
Study Summary
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
Primary Outcome
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as an AE either reported for the first time or the worsening of a pre-existing event, after the first dose of study dru
Conditions Studied
Interventions
- DRUG INCAGN02385
- DRUG INCAGN02390
- DRUG INCMGA00012.
Study Locations (17)
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- H Lee Moffitt Cancer Center and Research - Tampa
Pennsylvania
- Penn State Hershey Cancer Institute - Hershey
- Hillman Cancer Center - Pittsburgh
California
- The Angeles Clinic and Research Institute - Los Angeles
Iowa
- University of Iowa - Iowa City
Maryland
- Cancer Center For Blood Disorders A Division of American Oncology Partners P.A - Bethesda
Missouri
- Washington University - St Louis
New Jersey
- John Theurer Cancer Center, Hackensack University Medical Center - Hackensack
New York
- Nyu Langone Laura and Isaac Perlmutter Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2025-08-25 |
| Phase | Phase 1 |
What the finished NCT04370704 record still lists
NCT04370704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which INCAGN02385 is the first listed.
NCT04370704 lists 17 locations in 15 states (Florida, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT04370704 about?
NCT04370704 is a clinical study titled "Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies". The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
What is the current status of trial NCT04370704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2020-07-27. Estimated completion is 2025-08-25.
What conditions does trial NCT04370704 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04370704?
The interventions under investigation include: INCAGN02385 (DRUG), INCAGN02390 (DRUG), INCMGA00012. (DRUG).
Who is sponsoring clinical trial NCT04370704?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370704 being conducted?
This trial has 17 study locations across California, Florida, Iowa, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04370704's enrollment target sits among peer trials
61 150th of 266 higher than 116 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI